Short Interest in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) Increases By 75.3%

Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) saw a significant growth in short interest during the month of February. As of February 15th, there was short interest totalling 4,750,000 shares, a growth of 75.3% from the January 31st total of 2,710,000 shares. Currently, 44.9% of the company’s shares are sold short. Based on an average trading volume of 18,790,000 shares, the days-to-cover ratio is currently 0.3 days.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Hepion Pharmaceuticals stock. Anson Funds Management LP purchased a new stake in Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 231,849 shares of the company’s stock, valued at approximately $155,000. Anson Funds Management LP owned about 3.33% of Hepion Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). 17.24% of the stock is owned by institutional investors and hedge funds.

Hepion Pharmaceuticals Stock Down 11.2 %

Shares of NASDAQ HEPA traded down $0.02 on Friday, hitting $0.13. The company had a trading volume of 4,828,291 shares, compared to its average volume of 31,504,930. Hepion Pharmaceuticals has a 12-month low of $0.12 and a 12-month high of $3.33. The business has a 50 day moving average of $0.32 and a two-hundred day moving average of $0.55. The firm has a market capitalization of $876,708.00, a P/E ratio of -0.03 and a beta of 1.65.

Hepion Pharmaceuticals Company Profile

Hepion Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of drug therapy treatment for chronic liver diseases in the United States. It develops Rencofilstat, a cyclophilin inhibitor that has completed Phase 2a clinical trials to target multiple pathologic pathways involved in the progression of liver disease; and is in phase 2 clinical development for the treatment of non-alcoholic steatohepatitis (NASH), as well as preclinical studies of Rencofilstat shows reduction in liver fibrosis, liver inflammation, liver tumor burden, and titers of HBV, HCV, HDV, and HIV-1, and has demonstrated antiviral activities for hepatitis B, C, and D viruses through several mechanisms.